Cargando…

PB1953: TWELVE CASES OF MULTICENTRIC CASTLEMAN DISEASE WITH ELEVATED SERUM IGG4 LEVELS AND INFILTRATING IGG4 POSITIVE PLASMA CELLS PATHOLOGICALLY FROM A SINGLE CENTER.

Detalles Bibliográficos
Autores principales:	Dai, Shishuo, Wu, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430357/ http://dx.doi.org/10.1097/01.HS9.0000974628.94354.89

Ejemplares similares

PB2285: DIVERSITY OF IGG4-RELATED DISEASE: A CASE SERIES OF FOUR PATIENTS
por: Hanani, Hind, et al.
Publicado: (2023)

Diffuse cryptococcal pneumonia in multicentric Castleman’s disease with elevated serum IgG(4)
por: Takiguchi, Junji, et al.
Publicado: (2023)

PB2116: CASTLEMAN’S DISEASE: DIFFERENT CLINICAL BEHAVIOR AND PATHOLOGIC RECLASSIFICATION OF A COHORT OF MEXICAN PATIENTS
por: Collazo, Alfonso Orozco, et al.
Publicado: (2023)

PB2708: SYMPTOM BURDEN AND ITS IMPACT ON DAILY LIFE IN PATIENTS WITH IDIOPATHIC MULTICENTRIC CASTLEMAN’S DISEASE (IMCD): AN EXPLORATORY ANALYSIS OF THE SURVEY’S INTERNAL CONSTRUCT VALIDITY
por: Franklin, Matt, et al.
Publicado: (2023)

PB2152: THE CLINICAL PICTURE OF CASTLEMAN DISEASE – A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Kanhai, Karan, et al.
Publicado: (2023)

Tocilizumab-effective multicentric Castleman's disease with infiltration of eosinophil and IgG(4)-positive plasma cells: A case report
por: Katsumata, Yusuke, et al.
Publicado: (2018)

PB1953: ASSESSMENT OF THE EFFICACY OF BORTEZOMIB-CONTAINING THERAPY REGIMENS DEPENDING ON MAGE-C1 GENE EXPRESSION IN MULTIPLE MYELOMA PATIENTS.
por: Eleonora, M., et al.
Publicado: (2022)

Idiopathic Multicentric Castleman Disease with Strikingly Elevated IgG4 Concentration in the Serum and Abundant IgG4-Positive Cells in the Tissue: A Case Report
por: Cheng, Chia-Chun, et al.
Publicado: (2022)

Idiopathic multicentric Castleman's disease: a clinicopathologic study in comparison with IgG4-related disease
por: Otani, Kyoko, et al.
Publicado: (2018)

Distinct features distinguishing IgG4-related disease from multicentric Castleman’s disease
por: Sasaki, Takanori, et al.
Publicado: (2017)

Investigation of IgG4‐positive cells in idiopathic multicentric Castleman disease and validation of the 2020 exclusion criteria for IgG4‐related disease
por: Nishikori, Asami, et al.
Publicado: (2021)

Overlap of IgG4-related Disease and Multicentric Castleman's Disease in a Patient with Skin Lesions
por: Mochizuki, Hiroki, et al.
Publicado: (2017)

PB2086: CHRONIC LYMPHOPROLIFERATIVE DISORDER OF NK CELLS WITH LIVER INFILTRATION
por: Otasevic, V., et al.
Publicado: (2022)

PB1936: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND THROMBOSIS: A MULTICENTRIC RETROSPECTIVE STUDY
por: Chatzileontiadou, S., et al.
Publicado: (2022)

PB2635: FEATURES OF PLATELET PATHOLOGY IN PREGNANT WOMEN
por: Zaynutdinova, Dilafruz, et al.
Publicado: (2023)

Pathologies Associated with Serum IgG4 Elevation
por: Ebbo, Mikael, et al.
Publicado: (2012)

Pulmonary Manifestations of Plasma Cell Type Idiopathic Multicentric Castleman Disease: A Clinicopathological Study in Comparison with IgG4-Related Disease
por: Nishimura, Midori Filiz, et al.
Publicado: (2020)

PB1988: EXTRAMEDULLARY BLAST CRISIS PRESENTING AS INFILTRATIVE OPTIC NEURITIS: A TREATMENT DILEMMA
por: Lina, Nezille Joy
Publicado: (2023)

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab
por: van Rhee, Frits, et al.
Publicado: (2020)

PB2158: EXPLORING THE BIOLOGICAL ROLE OF LILRA4 IN MANTLE CELL LYMPHOMA
por: Blum, M. K., et al.
Publicado: (2022)

PB2177: MULTICENTRE RETROSPECTIVE OBSERVATIONAL STUDY ON PATIENTS WITH MYELOFIBROSIS IN PIEDMONT. ROLE OF INFLAMMATION AND DYSIMMUNITY. MFACTORS STUDY.
por: Bonuomo, Valentina, et al.
Publicado: (2023)

PB2389: DIAGNOSTIC SIGNIFICANCE OF CYTOKINE EXPRESSION LEVELS IN CEREBROSPINAL FLUID FOR CENTRAL NERVOUS SYSTEM INFILTRATION OF LYMPHOMA
por: Xin, Luo, et al.
Publicado: (2023)

Polymyositis with elevated serum IgG4 levels and abundant IgG4(+) plasma cell infiltration: A case report and literature review
por: Anan, Ryusuke, et al.
Publicado: (2017)

PB2004: CHRONIC MYELOMONOCYTIC LEUKEMIA AND CONCOMITANT MONOCLONAL GAMMOPATHY: A MULTICENTRE RETROSPECTIVE STUDY OF CLINICAL CHARACTERISTICS, PREVALENCE AND OUTCOME
por: Diral, Elisa, et al.
Publicado: (2023)

PB1967: ROLE OF CYTOKINES IN MULTIPLE MYELOMA: IL-1RN AND IL-4 VNTR POLYMORPHISMS
por: Serin, I., et al.
Publicado: (2022)

PB1778: NB4 CELLS CAN SURVIVE DURING ATO TREATMENT BY REGULATING THE NUMBER OF MITOCHONDRIA
por: Ding, S., et al.
Publicado: (2022)

PB1982: DEEPENING OF RESPONSE IN PATIENTS WITH MULTIPLE MYELOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION: A MULTICENTRIC STUDY IN A LATINO POPULATION
por: Bourlon, C., et al.
Publicado: (2022)

PB2395: ASSOCIATIONS BETWEEN GLYCOLYSIS PATTERNS AND IMMUNE CELL INFILTRATION IN THE TUMOR MICROENVIRONMENT IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS
por: Liu, Zhenyu, et al.
Publicado: (2023)

PB2272: THERAPY AND HOSPITAL MORTALITY PREDICTORS IN HEMATOLOGICAL PATIENTS WITH 4 GRADE NEUTROPENIA AND CONCOMITANT CORONAVIRUS INFECTION
por: Kaluzskaya, K., et al.
Publicado: (2022)

PB2400: THE EFFECT OF BONE MARROW CD4/CD8+ RATIO ON RESPONSE TO TREATMENT AND SURVIVAL IN LYMPHOMAS
por: Can Cavdar, Vahit, et al.
Publicado: (2023)

PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION
por: Dale, D. C., et al.
Publicado: (2022)

PB1828: REALGAR (AS4S4), A TRADITIONAL CHINESE MEDICINE, INDUCES ACUTE PROMYELOCYTIC LEUKEMIA CELL DEATH VIA THE BCL-2/BAX/CYT-C/AIF SIGNALING PATHWAY IN VITRO
por: LI, Zonghong, et al.
Publicado: (2023)

PB2351: TRIAL IN PROGRESS: A PHASE 2, MULTICENTRE STUDY OF BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY IN FRONTLINE TREATMENT OF CHINESE PATIENTS WITH CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMAS
por: Song, Yuqin, et al.
Publicado: (2023)

PB2073: EVALUATION OF THE PLASMA METABOLOMIC PROFILE OF MGUS AND MULTIPLE MYELOMA PATIENTS
por: Ciesluk, Klaudia, et al.
Publicado: (2023)

PB1720: STUDY ON THE MECHANISM OF ZHIGANCAO DECOCTION REGULATING MIRNA-21/ TLR4/ MAPK PATHWAY TO IMPROVE DOXORUBICIN-INDUCED MYOCARDIAL APOPTOSIS
por: LI, Suzhen, et al.
Publicado: (2023)

PB1967: EVALUATION OF A TRIAL OF IMATIB* DOSE TAPERING IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: RESULTS AT 4.5 YEARS
por: Abdennebi, Naima, et al.
Publicado: (2023)

PB2329: ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA (EATL): MULTICENTRIC REVIEW OF CLINICAL FEATURES AND TREATMENT: ON BEHALF OF GELTAMO (GRUPO ESPAÑOL DE LINFOMAS Y TRASPLANTES DE MÉDULA ÓSEA)
por: Infante, Maria Stefania, et al.
Publicado: (2023)

PB1866: RESPONSE TO NOVEL ANTI CD20 ANTIBODY AND BCL2 INHIBITOR IN A PATIENT WITH CLL AND MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS ASSOCIATED WITH LEUKEMIC KIDNEY INFILTRATION AND REVIEW OF LITERATURE
por: Goanta, J. G., et al.
Publicado: (2022)

Relationship between chronic sclerosing dacryoadenitis with high level of IgG4 and Castleman disease
por: Oshitari, Toshiyuki, et al.
Publicado: (2011)

Inflammatory pseudotumor of Castleman disease and IgG4-related disease masquerading as kidney malignancy
por: Liu, Bolong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9a76cqu2d2b7pq9gf6dvu81i3k